Bristol Myers Squibb (BMY) Non-Current Debt (2009 - 2026)

Bristol Myers Squibb has disclosed Non-Current Debt across 18 years of filings, most recently posting $42.2 billion for Q1 2026.

• In Q1 2026, Non-Current Debt fell 8.68% year-over-year to $42.2 billion; the TTM figure through Mar 2026 stood at $42.2 billion (down 8.68% YoY), while the FY2025 annual figure was $42.8 billion, down 9.98% from the prior year.
• Non-Current Debt slipped to $42.2 billion in Q1 2026, from $42.8 billion in the prior quarter.
• Over the last five years, Non-Current Debt for BMY reached as high as $49.5 billion in Q1 2024 and fell as low as $32.1 billion in Q3 2023.
• The 5-year median for Non-Current Debt is $42.2 billion (2026), against an average of $41.2 billion.
• Annual changes were most pronounced in 2022 — Non-Current Debt slipped 15.85% — and 2024, when it surged 51.46%.
• A 5-year view of Non-Current Debt shows it stood at $35.1 billion in 2022, then rose by 4.56% to $36.7 billion in 2023, then grew by 29.87% to $47.6 billion in 2024, then slipped by 9.98% to $42.8 billion in 2025, then fell by 1.63% to $42.2 billion in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $42.2 billion, $42.8 billion, and $44.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.